Home Companies Catalysts Deep Dives
BLINCYTO blinatumomab APPROVED
Drug Profile
ModalityBispecific T-cell engager (BiTE)
RouteIV
Therapy AreaOncology
Launch2014-12-03
Peak Sales Est$2500M
Formulations[{"id":"blincyto-iv","doses":"9mcg/day (Cycle 1 Week 1) -> 28mcg/day","route":"IV","setting":"INFUSI
Companies
AMGN (ORIGINATOR)100%
Mechanism: CD19/CD3 BiTE (bispecific T-cell engager)
Expert: Bispecific T-cell engager bridging CD3 on T-cells and CD19 on B-lineage malignant cells. Continuous IV infusion. Induces T-cell proliferation and redirected lysis.
Everyday: Connects a patient's own T-cells directly to leukemia cells by bridging CD19 (on cancer) and CD3 (on T-cells). Forces the immune system to kill the cancer at close range.
Targets: ["CD19","CD3"]
Revenue History
PeriodRevenue ($M)
2024$1,216M
2025$1,559M
Q4 2024$381M
Q4 2025$413M
Programs (1)
IndicationStageKey StudyRegional Status
Ph- B-ALL MRD+APPROVEDBLAST[{"stage":"APPROVED","region":"US","approval_date":"2014-12-03"},{"stage":"APPRO
Notes
+28% YoY. Moving to 1L ALL (Golden Gate Ph3). SC formulation in development to improve convenience. First-in-class BiTE technology.
Data from Supabase · Updated 2026-03-24